In the context of medications in all patients and in the CAD and non-CAD groups, the percentages of the use of angiotensin II receptor blockers (ARBs)/angiotensin-converting enzyme inhibitors (ACE-Is), calcium channel blockers (CCBs), β-blockers, and statins in all patients were 36%, 39%, 9%, and 31%, respectively. This evidence concerns the gene ACE and coronary artery disorder.